Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours (Q36892294)

16 August 2017

1 reference

title

Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours (English)

1 reference

16 August 2017

Martijn Van Essen

1

1 reference

16 August 2017

Eric P Krenning

2

1 reference

16 August 2017

Marion De Jong

3

1 reference

16 August 2017

Roelf Valkema

4

1 reference

16 August 2017

Dik J Kwekkeboom

5

1 reference

16 August 2017

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

46

1 reference

16 August 2017

6

1 reference

16 August 2017

723-734

1 reference

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

16 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

A 5-decade analysis of 13,715 carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Treatment of the carcinoid tumor and the malignant carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

A phase II study of docetaxel in patients with metastatic carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Chemotherapy for gastro-enteropancreatic endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Clinical and in vitro studies of imatinib in advanced carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701441848

10.1080/02841860701441848

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference